Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is a prodrug that is taken up by skin cells and converted into protoporphyrin IX. When the area is exposed to red light, protoporphyrin IX produces reactive oxygen species that cause targeted cell death in dysplastic or cancerous tissue while sparing surrounding healthy skin.

The prescribed dose of Metvix is determined by the treating clinician. Typically, a thin layer of the 16% cream is applied to the lesion, covered for a defined incubation period, and then illuminated. Exact application amount, incubation time, and light dose are individualized per patient.

Safety of Metvix in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Metvix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Metvix is aminolevulinic acid‑based creams such as Ameluz. Both are photosensitizers used in photodynamic therapy, but methyl aminolevulinate (Metvix) often provides deeper tissue penetration and may require a shorter incubation time, while aminolevulinic acid formulations may have different illumination protocols.

Metvix should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from light and moisture, and avoid freezing. Do not use the product if the seal is broken or the cream appears discoloured.

Metvix is applied topically as a thin layer to the target skin lesion. After a prescribed incubation period (usually a few hours), the area is illuminated with a red‑light source of specific wavelength. The procedure is performed by a trained healthcare professional in a clinical setting.

Serious risks include severe phototoxic reactions that can affect surrounding skin, secondary infection of the treated area, and allergic contact dermatitis. Patients should be monitored for excessive pain, swelling, or signs of infection and instructed to seek medical attention promptly if these occur.

Metvix is contraindicated in patients with known hypersensitivity to methyl aminolevulinate or any cream excipients, and in individuals with porphyria or other photosensitivity disorders. It should also be avoided in patients who cannot comply with post‑treatment light‑avoidance instructions.